Decoy Therapeutics Inc
DCOY Healthcare Biotechnology
In the quarter to June 2026, revenue fell 84.6%, EPS grew 94.5% and free cash flow fell 212.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow DCOY
Decoy Therapeutics Inc (DCOY) EV/Sales
As of 16 October 2026, Decoy Therapeutics Inc (DCOY) trades at a EV/Sales of −3.5×. Over the past ten years it has ranged from −11.0× (December 2018) to 92,641,612× (March 2018); the current reading is higher than 7% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2021 | −2.7× | — |
| FY2020 | 0.5× | (84.65%) |
| FY2019 | 3.1× | — |
| FY2018 | −3.1× | — |
| FY2017 | 43,395,268× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | −1.9× | — |
| Dec 2021 | −2.7× | — |
| Jun 2021 | 2.8× | 132.35% |
| Mar 2021 | 1.2× | 156.85% |
| 19 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| VIVS VivoSim Labs, Inc. compare | −7.4× |
| ONCO Onconetix, Inc. compare | −7.3× |
| DCOY Decoy Therapeutics Inc | −3.5× |
| ARAV ARAVIVE, INC compare | −0.4× |
| APVO Aptevo Therapeutics Inc. compare | −0.3× |
| GRI GRI Bio, Inc. compare | n/m |
| REVB Revelation Biosciences, Inc. compare | n/m |
| MBIO Mustang Bio, Inc. compare | n/m |
| BCAB BioAtla, Inc. compare | 0.6× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)